Literature DB >> 25690737

Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes.

Pamela Bachour-El Azzi1, Ahmad Sharanek2, Audrey Burban2, Ruoya Li3, Rémy Le Guével3, Ziad Abdel-Razzak3, Bruno Stieger2, Christiane Guguen-Guillouzo3, André Guillouzo4.   

Abstract

The role of hepatobiliary transporters in drug-induced liver injury remains poorly understood. Various in vivo and in vitro biological approaches are currently used for studying hepatic transporters; however, appropriate localization and functional activity of these transporters are essential for normal biliary flow and drug transport. Human hepatocytes (HHs) are considered as the most suitable in vitro cell model but erratic availability and inter-donor functional variations limit their use. In this work, we aimed to compare localization of influx and efflux transporters and their functional activity in differentiated human HepaRG hepatocytes with fresh HHs in conventional (CCHH) and sandwich (SCHH) cultures. All tested influx and efflux transporters were correctly localized to canalicular [bile salt export pump (BSEP), multidrug resistance-associated protein 2 (MRP2), multidrug resistance protein 1 (MDR1), and MDR3] or basolateral [Na(+)-taurocholate co-transporting polypeptide (NTCP) and MRP3] membrane domains and were functional in all models. Contrary to other transporters, NTCP and BSEP were less abundant and active in HepaRG cells, cellular uptake of taurocholate was 2.2- and 1.4-fold and bile excretion index 2.8- and 2.6-fold lower, than in SCHHs and CCHHs, respectively. However, when taurocholate canalicular efflux was evaluated in standard and divalent cation-free conditions in buffers or cell lysates, the difference between the three models did not exceed 9.3%. Interestingly, cell imaging showed higher bile canaliculi contraction/relaxation activity in HepaRG hepatocytes and larger bile canaliculi networks in SCHHs. Altogether, our results bring new insights in mechanisms involved in bile acids accumulation and excretion in HHs and suggest that HepaRG cells represent a suitable model for studying hepatobiliary transporters and drug-induced cholestasis.
© The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology.All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HepaRG hepatocytes; hepatobiliary transporters; human hepatocytes; membrane localization; transporter activity

Mesh:

Substances:

Year:  2015        PMID: 25690737      PMCID: PMC4833040          DOI: 10.1093/toxsci/kfv041

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  46 in total

Review 1.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 2.  Drug-induced liver injury: the role of drug metabolism and transport.

Authors:  Alberto Corsini; Michele Bortolini
Journal:  J Clin Pharmacol       Date:  2013-02-22       Impact factor: 3.126

3.  Automated detection of hepatotoxic compounds in human hepatocytes using HepaRG cells and image-based analysis of mitochondrial dysfunction with JC-1 dye.

Authors:  K Pernelle; R Le Guevel; D Glaise; C Gaucher-Di Stasio; T Le Charpentier; B Bouaita; A Corlu; C Guguen-Guillouzo
Journal:  Toxicol Appl Pharmacol       Date:  2011-05-04       Impact factor: 4.219

4.  The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions.

Authors:  Patrik Lundquist; Johan Lööf; Anna-Karin Sohlenius-Sternbeck; Eva Floby; Jenny Johansson; Johan Bylund; Janet Hoogstraate; Lovisa Afzelius; Tommy B Andersson
Journal:  Drug Metab Dispos       Date:  2014-01-06       Impact factor: 3.922

5.  Polarized expression of drug transporters in differentiated human hepatoma HepaRG cells.

Authors:  Marc Le Vee; Gregory Noel; Elodie Jouan; Bruno Stieger; Olivier Fardel
Journal:  Toxicol In Vitro       Date:  2013-07-12       Impact factor: 3.500

Review 6.  Hepatic transport of bile salts.

Authors:  G A Kullak-Ublick; B Stieger; B Hagenbuch; P J Meier
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver.

Authors:  Maciej J Zamek-Gliszczynski; Hao Xiong; Nita J Patel; Ryan Z Turncliff; Gary M Pollack; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

8.  Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.

Authors:  Pär Matsson; Jenny M Pedersen; Ulf Norinder; Christel A S Bergström; Per Artursson
Journal:  Pharm Res       Date:  2009-05-07       Impact factor: 4.200

9.  Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells.

Authors:  Pamela Bachour-El Azzi; Ahmad Sharanek; Ziad Abdel-Razzak; Sebastien Antherieu; Houssein Al-Attrache; Camille C Savary; Sylvie Lepage; Isabelle Morel; Gilles Labbe; Christiane Guguen-Guillouzo; André Guillouzo
Journal:  Drug Metab Dispos       Date:  2014-07-07       Impact factor: 3.922

Review 10.  Oxidative stress: a radical way to stop making bile.

Authors:  Marcelo G Roma; Enrique J Sanchez Pozzi
Journal:  Ann Hepatol       Date:  2008 Jan-Mar       Impact factor: 2.400

View more
  18 in total

1.  Bile Acid-Induced Toxicity in HepaRG Cells Recapitulates the Response in Primary Human Hepatocytes.

Authors:  Benjamin L Woolbright; Mitchell R McGill; Huimin Yan; Hartmut Jaeschke
Journal:  Basic Clin Pharmacol Toxicol       Date:  2015-08-13       Impact factor: 4.080

Review 2.  A Change in Bile Flow: Looking Beyond Transporter Inhibition in the Development of Drug-induced Cholestasis.

Authors:  Brandy Garzel; Lei Zhang; Shiew-Mei Huang; Hongbing Wang
Journal:  Curr Drug Metab       Date:  2019       Impact factor: 3.731

3.  Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.

Authors:  Anika Mann; Thomas Pelz; Knut Rennert; Alexander Mosig; Michael Decker; Amelie Lupp
Journal:  Hum Cell       Date:  2017-05-19       Impact factor: 4.174

4.  From street to lab: in vitro hepatotoxicity of buphedrone, butylone and 3,4-DMMC.

Authors:  Rita Roque Bravo; Helena Carmo; Maria João Valente; João Pedro Silva; Félix Carvalho; Maria de Lourdes Bastos; Diana Dias da Silva
Journal:  Arch Toxicol       Date:  2021-02-07       Impact factor: 5.153

5.  Optimization of Canalicular ABC Transporter Function in HuH-7 Cells by Modification of Culture Conditions.

Authors:  Hee Eun Kang; Melina M Malinen; Chitra Saran; Paavo Honkakoski; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-08-01       Impact factor: 3.922

6.  ZIP14 is degraded in response to manganese exposure.

Authors:  Khristy J Thompson; Marianne Wessling-Resnick
Journal:  Biometals       Date:  2019-09-20       Impact factor: 2.949

7.  Protein expression and function of organic anion transporters in short-term and long-term cultures of Huh7 human hepatoma cells.

Authors:  Melina M Malinen; Katsuaki Ito; Hee Eun Kang; Paavo Honkakoski; Kim L R Brouwer
Journal:  Eur J Pharm Sci       Date:  2019-01-24       Impact factor: 4.384

8.  Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.

Authors:  Ahmad Sharanek; Audrey Burban; Matthew Burbank; Rémy Le Guevel; Ruoya Li; André Guillouzo; Christiane Guguen-Guillouzo
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

9.  Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury.

Authors:  Lindsey Devisscher; Mathieu Vinken; Eva Gijbels; Vânia Vilas-Boas; Pieter Annaert; Tamara Vanhaecke
Journal:  Arch Toxicol       Date:  2020-03-10       Impact factor: 5.153

10.  Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures.

Authors:  Robim M Rodrigues; Laxmikanth Kollipara; Umesh Chaudhari; Agapios Sachinidis; René P Zahedi; Albert Sickmann; Annette Kopp-Schneider; Xiaoqi Jiang; Hector Keun; Jan Hengstler; Marlies Oorts; Pieter Annaert; Eef Hoeben; Eva Gijbels; Joery De Kock; Tamara Vanhaecke; Vera Rogiers; Mathieu Vinken
Journal:  Arch Toxicol       Date:  2018-05-14       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.